Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MEA115575: A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study of Mepolizumab Adjunctive Therapy to Reduce Steroid Use in Subjects with Severe Refractory Asthma

Trial Profile

MEA115575: A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study of Mepolizumab Adjunctive Therapy to Reduce Steroid Use in Subjects with Severe Refractory Asthma

Completed
Phase of Trial: Phase III

Latest Information Update: 01 May 2019

At a glance

  • Drugs Mepolizumab (Primary) ; Prednisolone; Prednisone
  • Indications Asthma
  • Focus Pharmacogenomic; Registrational; Therapeutic Use
  • Acronyms SIRIUS
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 01 May 2019 Results assessing disease burden and efficacy of mepolizumab in patients with severe asthma and blood eosinophil counts of >/=150-300cells/muL using data from DREAM, MENSA, SIRIUS and MUSCA studies, published in the Respiratory Medicine
    • 19 Sep 2018 Results of a post-hoc analysis from NCT01000506, NCT01691521, NCT02281318, NCT01691508 and NCT02377427 studies, presented at the 28th Annual Congress of the European Respiratory Society.
    • 24 May 2017 Results of a post-hoc analysis presented at the 113th International Conference of the American Thoracic Society.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top